ANXA5 and central nervous system cancer: Moreover, as described for axitinib monotherapy in T98 and U87, neither Annexin V positive cells, apoptotic DNA fragmentation or caspase-3 activity (Supplementary Figure S7A-S7C) were evidenced in axitinib plus bortezomib treated U251 glioma cells.